Mission Dermatology
Welcome,         Profile    Billing    Logout  
 1 Trial 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yoelin, Steve G
NCT05083286: Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines

Recruiting
1
40
US
OnabotulinumtoxinA, Botox
Clinical Testing of Beverly Hills, Allergan
Glabellar Frown Lines
08/22
08/22
PEARL-1, NCT04540900: A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

Recruiting
1
85
US
KB301, Placebo
Krystal Biotech, Inc.
Skin Roughness, Wrinkle, Fine Lines, Skin Thickness
05/24
05/29
Guide, Shireen
NCT04917874: A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Completed
3
47
US
Open Label Topical Beremagene Geperpavec (B-VEC)
Krystal Biotech, Inc.
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
07/23
07/23
NCT06073132: An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Recruiting
2/3
80
Europe, US, RoW
AC-203, Vehicle
TWi Biotechnology, Inc.
Generalized Epidermolysis Bullosa Simplex
08/25
03/26
NCT05970497: A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Recruiting
1
80
US
KB707
Krystal Biotech, Inc.
Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma, Osteosarcoma, Carcinoma, Squamous Cell, Carcinoma, Basal Cell
07/26
07/26
NCT04917887: Long-Term Follow-up Protocol

Recruiting
N/A
50
US
Krystal Biotech, Inc.
Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
05/28
05/28
Pot, Sera
PEARL-1, NCT04540900: A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

Recruiting
1
85
US
KB301, Placebo
Krystal Biotech, Inc.
Skin Roughness, Wrinkle, Fine Lines, Skin Thickness
05/24
05/29

Download Options